Taysha Gene Therapies
On a mission to eradicate monogenic CNS disease.
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $200m | Post IPO Equity |
| Total Funding | 000k | ||
PBM Capital Group(exited)
Fidelity Investments(exited)
Nolan Capital(exited)
BlackRock(exited)
GV(exited)
Invus(exited)
Casdin Capital(exited)
Franklin Templeton Investments(exited)
Octagon Capital Partners(exited)
Perceptive Advisors(exited)
Sands Capital Management(exited)
ArrowMark Partners(exited)
Venrock(exited)
Silicon Valley Bank(exited)
Astellas Pharma(exited)
Octagon Capital Advisors(exited)
Octagon Capital Advisors(exited)
Bios Partners(exited)
Standard Treasury(exited)
RTW Investments(exited)
RA Capital Management(exited)
Acuta Capital Partners(exited)
TCGX(exited)
Kynam Capital Management(exited)
B Capital Group(exited)
GordonMD Global Investment(exited)
Trinity Capital(exited)
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 518 % | (46 %) | (14 %) | (31 %) | 1212 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (5028 %) | (440 %) | (998 %) | (1293 %) | (2238 %) | 126 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (6635 %) | (722 %) | (1072 %) | (1316 %) | (2139 %) | (108 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 3644 % | 367 % | 792 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.